181 related articles for article (PubMed ID: 33051740)
1. Verification of the Optimal Interval Before Esophagectomy After Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer.
Wakita A; Motoyama S; Sato Y; Nagaki Y; Fujita H; Terata K; Imai K; Minamiya Y
Ann Surg Oncol; 2021 Apr; 28(4):2101-2110. PubMed ID: 33051740
[TBL] [Abstract][Full Text] [Related]
2. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Saeki H; Nakashima Y; Zaitsu Y; Tsuda Y; Kasagi Y; Ando K; Imamura Y; Ohgaki K; Ito S; Kimura Y; Egashira A; Oki E; Morita M; Maehara Y
Surg Today; 2016 Mar; 46(3):261-7. PubMed ID: 25740123
[TBL] [Abstract][Full Text] [Related]
3. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Neoadjuvant Chemoradiotherapy Following Esophagectomy with Japanese-style Extended 3-Field Lymphadenectomy for Thoracic Esophageal Cancer.
Motoyama S; Sato Y; Sasaki T; Wakita A; Kawakita Y; Liu J; Nagaki Y; Saito H; Imai K; Konno H; Mizusawa KT; Minamiya Y
Anticancer Res; 2017 Oct; 37(10):5837-5843. PubMed ID: 28982909
[TBL] [Abstract][Full Text] [Related]
5. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
[TBL] [Abstract][Full Text] [Related]
6. SUV
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
[TBL] [Abstract][Full Text] [Related]
7. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis.
Tie H; He F; Shen J; Zhang B; Ye M; Chen B; Wu Q
Dis Esophagus; 2018 Jan; 31(1):1-9. PubMed ID: 29087451
[TBL] [Abstract][Full Text] [Related]
8. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
9. Preoperative chemoradiation therapy for esophageal cancer is a risk factor for the elevation of high mobility group box-1, leading to an increase in postoperative severe pulmonary complications.
Takahata R; Ono S; Tsujimoto H; Hiraki S; Aosasa S; Yamamoto J; Hase K
Dis Esophagus; 2016 Jan; 29(1):70-8. PubMed ID: 25139532
[TBL] [Abstract][Full Text] [Related]
10. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.
Qin Q; Xu H; Liu J; Zhang C; Xu L; Di X; Zhang X; Sun X
Int J Surg; 2018 Nov; 59():11-18. PubMed ID: 30261331
[TBL] [Abstract][Full Text] [Related]
11. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.
Klevebro F; Nilsson K; Lindblad M; Ekman S; Johansson J; Lundell L; Ndegwa N; Hedberg J; Nilsson M
Dis Esophagus; 2020 May; 33(5):. PubMed ID: 31676895
[TBL] [Abstract][Full Text] [Related]
12. [Is esophagectomy necessary for esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy].
Fu J; Tan Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):983-986. PubMed ID: 30269316
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life following neoadjuvant chemoradiotherapy versus perioperative chemotherapy and esophagectomy for esophageal cancer: a European multicenter study.
Schuring N; Markar SR; Hagens ERC; Jezerskyte E; Sprangers MAG; Lagergren P; Johar A; Gisbertz SS; van Berge Henegouwen MI;
Dis Esophagus; 2023 Mar; 36(4):. PubMed ID: 36241253
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and risk factors of anastomotic leakage after radical esophagectomy].
Chen C; Yu Z; Jin Q; Zhang X
Zhonghua Wai Ke Za Zhi; 2015 Jul; 53(7):518-21. PubMed ID: 26359075
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of minimally invasive esophagectomy in esophageal cancer after neoadjuvant chemoradiotherapy.
Warner S; Chang YH; Paripati H; Ross H; Ashman J; Harold K; Day R; Stucky CC; Rule W; Jaroszewski D
Ann Thorac Surg; 2014 Feb; 97(2):439-45. PubMed ID: 24266955
[TBL] [Abstract][Full Text] [Related]
19. Minimally Invasive Esophagectomy with Thoracic Duct Resection Post Neoadjuvant Chemoradiotherapy for Carcinoma Esophagus-Impact on Lymph Node Yield and Hemodynamic Parameters.
Anand S; Kalayarasan R; Chandrasekar S; Gnanasekaran S; Pottakkat B
J Gastrointest Cancer; 2019 Jun; 50(2):230-235. PubMed ID: 29344808
[TBL] [Abstract][Full Text] [Related]
20. [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].
Müller AK; Lenschow C; Palmes D; Senninger N; Hummel R; Lindner K
Chirurg; 2015 Sep; 86(9):874-80. PubMed ID: 25662991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
